Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like Eleven Bio Reports Fourth Quarter And Full Year 2016 Financial Results March 23, 2017 Spark's Good Week Continues With Signing of Huge Lease Near HQ December 7, 2017 Astrazeneca Gets Another Boost With FDA Approval of Severe Asthma Drug November 14, 2017
